Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
Open accessThe DOI matches its Crossref record; 148 of the 149 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N-methyl d-aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AD is characterized by neurodegeneration due to neuronal cell death, starting in the entorhinal cortex of the hippocampus, primarily affecting individuals aged 65 and older [1].”
From Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer’s Treatment: Systematic Review (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For ADs, precision medicine focuses on genetic and biomarker analysis to improve therapy approaches, risk assessment, and diagnosis.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“They may also be the cause of neuroinflammation by activating microglia and producing inflammatory cytokines.”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Early in AD progression, damage to neuronal connections occurs primarily in the medial temporal lobe and neocortical areas (Figure 2B) [42,43].”
From The Impact of Neurotoxin Proteins Trafficked by Primary Cilia and Extracellular Vesicles in Neurodegenerative Diseases (2025) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“The first disease-modifying medication for AD is a recombinant monoclonal antibody called aducanumab, also known by the brand name Aduhelm. It targets amyloid beta specifically [37]. It functions by lowering the quantity of amyloid deposits or brain plaques [130,131].”
From Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease (2024) · cites this paper as [37]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 2×
“At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [6,7].”
BackgroundRetractedTacrine for Alzheimer's disease
Qizilbash, N., Birks, J., López Arrieta, J., Lewington, S., & Szeto, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000202 · Cited by 82 · cited 1×
“Later on, several AChEIs were introduced, such as donepezil (2, Figure 4), rivastigmine (3, Figure 4), and galantamine (4, Figure 4), and are currently in use for the symptomatic treatment of AD [34,97,102,103].”
BackgroundRetractedLi, J.-G., Chiu, J., & Praticò, D. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0364-x · Cited by 51 · cited 1×
“The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [142].”
BackgroundRetractedRETRACTED ARTICLE: VPS35 regulates tau phosphorylation and neuropathology in tauopathy
Vagnozzi, A. N., Li, J.-G., Chiu, J., Razmpour, R., Warfield, R., Ramirez, S. H., & Praticò, D. (2021) · Molecular Psychiatry · doi:10.1038/s41380-019-0453-x · Cited by 36 · cited 1×
“A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [140,141].”
BackgroundRetractedMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · cited 1×
“All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, a…”
BackgroundMcKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · cited 1×
“ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [59].”
BackgroundNeuropathological alterations in Alzheimer disease
Serrano-Pozo, A., Frosch, M. P., Masliah, E., & Hyman, B. T. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006189 · Cited by 3,345
Ageing as a risk factor for neurodegenerative disease
Hou, Y., Dan, X., Babbar, M., Wei, Y., Hasselbalch, S. G., Croteau, D. L., & Bohr, V. A. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0244-7 · Cited by 3,310 · cited 1×
“These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [43,44].”
BackgroundThe cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Research works printed but not linked: 4
- Kumar A. Sidhu J. Goyal A. Alzheimer Disease StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK499922/ (accessed on 8 December 2020)
- Singh R. Sadiq N.M. Cholinesterase Inhibitors StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK544336/ (accessed on 8 December 2020)
- Kuns B. Rosani A. Varghese D. Memantine StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK500025/ (accessed on 8 December 2020)
- Kumar A. Sharma S. Donepezil StatPearls StatPearls Publishing Treasure Island, FL, USA 2020 Available online: https://www.ncbi.nlm.nih.gov/books/NBK513257/ (accessed on 8 December 2020)
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Clinical applications of stem cell-derived exosomes
Tan, F., Li, X., Wang, Z., Li, J., Shahzad, K., & Zheng, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01704-0 · Cited by 708
Inflammatory Processes in Alzheimer’s Disease—Pathomechanism, Diagnosis and Treatment: A Review
Twarowski, B., & Herbet, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076518 · Cited by 412
“During the pathomorphological examination of the brain of Auguste Deter, who suffered from episodes of memory loss and personality changes before her death, the scientist found the presence of amyloid deposits and massive neuronal degeneration in the collected dissection material and described the observed changes as…”
Gadhave, D. G., Sugandhi, V. V., Jha, S. K., Nangare, S. N., Gupta, G., Singh, S. K., Dua, K., Cho, H., Hansbro, P. M., & Paudel, K. R. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102357 · Cited by 358
“These deposits hinders the normal passage of impulses among nerve cells, leading to cell death and the gradual deterioration of brain tissue (Breijyeh and Karaman, 2020).”
BackgroundWięckowska-Gacek, A., Mietelska-Porowska, A., Wydrych, M., & Wojda, U. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101397 · Cited by 343
“…molecular mechanisms, several additional hypotheses of AD pathogenesis have been proposed including cholinergic, oxidative stress, mitochondrial cascade, calcium dyshomeostasis, neurovascular and lymphatic system hypotheses (Breijyeh and Karaman, 2020; Liu et al., 2019a; Wojsiat et al., 2018).”
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Maqbool, Z., Khalid, W., Atiq, H. T., Koraqi, H., Javaid, Z., Alhag, S. K., Al-Shuraym, L. A., Bader, D. M. D., Almarzuq, M., Afifi, M., et al. (2023) · Molecules · doi:10.3390/molecules28041636 · Cited by 227
Insulin Resistance and Diabetes Mellitus in Alzheimer’s Disease
Burillo, J., Marqués, P., Jiménez, B., González-Blanco, C., Benito, M., & Guillén, C. (2021) · Cells · doi:10.3390/cells10051236 · Cited by 225
Molecular Mechanism of Arsenic-Induced Neurotoxicity including Neuronal Dysfunctions
Thakur, M., Rachamalla, M., Niyogi, S., Datusalia, A. K., & Flora, S. J. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810077 · Cited by 207
“The brain is susceptible to oxidative stress because of its high energy requirement, and arsenic exposure causes oxidative stress damage via reduced antioxidant enzymes in the brain [21].”
BackgroundRole of Nrf2 in aging, Alzheimer’s and other neurodegenerative diseases
George, M., Tharakan, M., Culberson, J., Reddy, A. P., & Reddy, P. H. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101756 · Cited by 207
Blood–Brain Barrier Breakdown in Alzheimer’s Disease: Mechanisms and Targeted Strategies
Alkhalifa, A. E., Al-Ghraiybah, N. F., Odum, J., Shunnarah, J. G., Austin, N., & Kaddoumi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216288 · Cited by 212
“Additionally, vascular risk factors such as hypertension are linked with the development and progression of the disease [10,11].”
BackgroundMachine Learning for Dementia Prediction: A Systematic Review and Future Research Directions
Javeed, A., Dallora, A. L., Berglund, J. S., Ali, A., Ali, L., & Anderberg, P. (2023) · Journal of Medical Systems · doi:10.1007/s10916-023-01906-7 · Cited by 187
“Except for 1–2% of cases where deterministic genetic anomalies have been discovered, the aetiology of the majority of Alzheimer’s patients remains unexplained [12].”
BackgroundKale, M., Wankhede, N., Pawar, R., Ballal, S., Kumawat, R., Goswami, M., Khalid, M., Taksande, B., Upaganlawar, A., Umekar, M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102497 · Cited by 183
Bustamante-Barrientos, F. A., Luque-Campos, N., Araya, M. J., Lara-Barba, E., de Solminihac, J., Pradenas, C., Molina, L., Herrera-Luna, Y., Utreras-Mendoza, Y., Elizondo-Vega, R., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04493-w · Cited by 184
“…radicals can damage cellular lipids, proteins, and DNA, including mtDNA, which entails dysfunctional mitochondria associated with aging, and essentially, all chronic diseases include neurodegenerative pathologies (Aβ)-containing extracellular plaques derived from the amyloidogenic pathway [30].”
BackgroundThe chemistry of heterocycles in the 21st century
Charushin, V. N., Verbitskiy, E. V., Chupakhin, O. N., Vorobyeva, D. V., Gribanov, P. S., Osipov, S. N., Ivanov, A. V., Martynovskaya, S. V., Sagitova, E. F., Dyachenko, V. D., et al. (2024) · Russian Chemical Reviews · doi:10.59761/rcr5125 · Cited by 182
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Gao, X., Yu, X., Zhang, C., Wang, Y., Sun, Y., Sun, H., Zhang, H., Shi, Y., & He, X. (2022) · Stem Cell Reviews and Reports · doi:10.1007/s12015-022-10370-8 · Cited by 180
Payne, A., Nahashon, S., Taka, E., Adinew, G. M., & Soliman, K. F. A. (2022) · Biomolecules · doi:10.3390/biom12030371 · Cited by 165
“Present therapeutics are disease-modifying agents mainly focused on the Aβ propagation, but they have failed in clinical trials [35].”
BackgroundG protein-coupled receptors in neurodegenerative diseases and psychiatric disorders
Wong, T., Li, G., Li, S., Gao, W., Chen, G., Gan, S., Zhang, M., Li, H., Wu, S., & Du, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01427-2 · Cited by 197
“Deposition of the insoluble and phosphorylated β-amyloid peptide (derived from amyloid precursor protein) in the brain parenchyma of Alzheimer’s disease patients affects functions/regeneration of various forms of neurons.(9) The resulting widespread neuron damage affects synaptic communication leading to cognitive def…”
BackgroundAlzheimer’s Disease: Exploring the Landscape of Cognitive Decline
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00339 · Cited by 170
Baran, M. F., Keskin, C., Baran, A., Hatipoğlu, A., Yıldıztekin, M., Küçükaydın, S., Kurt, K., Hoşgören, H., Sarker, M. M. R., Sufianov, A. A., et al. (2023) · Molecules · doi:10.3390/molecules28052310 · Cited by 159
“The most often used method in the management and treatment of AD is acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitors such as donepezil, rivastigmine, and galantamine [61].”
MethodRole of Aβ in Alzheimer’s-related synaptic dysfunction
Zhang, H., Jiang, X., Ma, L., Wei, W., Li, Z., Chang, S., Wen, J., Sun, J., & Li, H. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.964075 · Cited by 209
“…synaptic plasticity, synapse toxicity Introduction AD is currently considered as a disease of synaptic failure (Babri et al., 2012), which is closely related to β-amyloid (Aβ) deposition and tau hyperphosphorylation (Kopeikina et al., 2012; Breijyeh and Karaman, 2020, Author Anonymous, 2020).”
BackgroundHsu, Y.-C., Huang, Y.-Y., Tsai, S., Kuo, Y., Lin, J., Ho, H.-H., Chen, J., Hsia, K.-C., & Sun, Y. (2023) · Nutrients · doi:10.3390/nu16010016 · Cited by 175
“AD is a neurodegenerative disease that results in a decline in cognitive function, and as of now, there is no curative treatment [38].”
BackgroundO-GlcNAcylation in health and neurodegenerative diseases
Lee, B. E., Suh, P., & Kim, J. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00709-5 · Cited by 155
Inflammation: A New Look at an Old Problem
Gusev, E., & Zhuravleva, Y. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094596 · Cited by 169
Valotto Neto, L. J., Reverete de Araujo, M., Moretti Junior, R. C., Mendes Machado, N., Joshi, R. K., dos Santos Buglio, D., Barbalho Lamas, C., Direito, R., Fornari Laurindo, L., Tanaka, M., et al. (2024) · Antioxidants · doi:10.3390/antiox13040393 · Cited by 146
The protective role of exercise against age-related neurodegeneration
Sujkowski, A., Hong, L., Wessells, R. J., & Todi, S. V. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101543 · Cited by 134
Long Non-Coding RNA (lncRNA) Roles in Cell Biology, Neurodevelopment and Neurological Disorders
Aliperti, V., Skonieczna, J., & Cerase, A. (2021) · Non-Coding RNA · doi:10.3390/ncrna7020036 · Cited by 137
“However, several other factors can cause neurodegeneration such as neuroinflammation and oxidative stress [131].”
BackgroundMoreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 153
“Thus, ChEI was developed to block the catalytic action of the AChE, resulting in increased levels of ACh in the synaptic cleft and activation of cholinergic receptors [1, 5].”
BackgroundInfluentialIncretin and insulin signaling as novel therapeutic targets for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., & Edison, P. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01792-4 · Cited by 136
“AD is characterized by a progressive loss of cognitive function, memory impairment, and decline in activities of daily living [2].”
BackgroundLaurindo, L. F., de Carvalho, G. M., de Oliveira Zanuso, B., Figueira, M. E., Direito, R., de Alvares Goulart, R., Buglio, D. S., & Barbalho, S. M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15010229 · Cited by 122
Pless, A., Ware, D., Saggu, S., Rehman, H., Morgan, J., & Wang, Q. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1263771 · Cited by 131
“For the diagnosis of AD to be made, other systemic, infectious, neurologic, psychiatric diseases, and medication side effects must be ruled out (Breijyeh and Karaman, 2020).”
BackgroundThe Role of BDNF as a Biomarker in Cognitive and Sensory Neurodegeneration
Pisani, A., Paciello, F., VECCHIO, V. D., Malesci, R., Corso, E. D., Cantone, E., & Fetoni, A. R. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040652 · Cited by 138
The Sheep as a Large Animal Model for the Investigation and Treatment of Human Disorders
Banstola, A., & Reynolds, J. N. J. (2022) · Biology · doi:10.3390/biology11091251 · Cited by 162
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Du, H., Meng, X., Yao, Y., & Xu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1033479 · Cited by 125
“However, all these treatments are symptomatic and cannot prevent or reverse AD pathology (81).”
BackgroundThe Role of TNF-α in Alzheimer’s Disease: A Narrative Review
Plantone, D., Pardini, M., Righi, D., Manco, C., Colombo, B. M., & De Stefano, N. (2023) · Cells · doi:10.3390/cells13010054 · Cited by 111
“Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that represents the most common cause of dementia in the elderly [1].”
BackgroundChen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
Adult hippocampal neurogenesis and its impairment in Alzheimer’s disease
Kim, T. A., Syty, M. D., Wu, K., & Ge, S. (2022) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2021.479 · Cited by 124
“The common indicators of AD are the presence of neurofibrillary tangles (NFTs), amyloid plaques, and synaptic loss (Breijyeh & Karaman, 2020).”
Alzheimer Disease Classification through Transfer Learning Approach
Raza, N., Naseer, A., Tamoor, M., & Zafar, K. (2023) · Diagnostics · doi:10.3390/diagnostics13040801 · Cited by 121
“However, early detection of this disease can help in taking preventative action at an early stage and can improve the symptoms of AD [4].”
BackgroundNADPH oxidases: redox regulation of cell homeostasis and disease
Kračun, D., Lopes, L. R., Cifuentes-Pagano, E., & Pagano, P. J. (2025) · Physiological Reviews · doi:10.1152/physrev.00034.2023 · Cited by 123
Fišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
Oxidative Stress, Endoplasmic Reticulum Stress and Apoptosis in the Pathology of Alzheimer’s Disease
Ekundayo, B. E., Obafemi, T. O., Adewale, O. B., Obafemi, B. A., Oyinloye, B. E., & Ekundayo, S. K. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01248-2 · Cited by 123
“Presently, there is no recognized treatment for Alzheimer ’ s disease; nevertheless, some drugs may alleviate its symptoms [1, 5, 8].”
Nucci, D., Sommariva, A., Degoni, L., Gallo, G., Mancarella, M., Natarelli, F., Savoia, A., Catalini, A., Ferranti, R., Pregliasco, F. E., et al. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-024-02718-6 · Cited by 120
“It is caused by a slowly progressing neurodegenerative accumulation of amyloid-beta peptides (Aβ) which cause neuritic plaques and neurofibrillary tangles [5].”
BackgroundAnalysis the Link between Periodontal Diseases and Alzheimer’s Disease: A Systematic Review
Borsa, L., Dubois, M., Sacco, G., & Lupi, L. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18179312 · Cited by 109
“Despite progress made in the last 30 years in the understanding of neuropathological mechanisms, particularly concerning tau and beta-amyloid processes [8], the question of the etiopathogeny and risk factors of AD is still debated [9,10].”
BackgroundA Potential Link Between Visceral Obesity and Risk of Alzheimer’s Disease
Al-Kuraishy, H. M., Al-Gareeb, A. I., Alsayegh, A. A., Hakami, Z. H., Khamjan, N. A., Saad, H. M., Batiha, G. E., & WAARD, M. M. D. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03817-4 · Cited by 113
“The processing and production of Aβ plaques affect neuronal activity through the interruption of synaptic activity and induction of cell death [86].”
BackgroundPathological mechanisms and treatment progression of Alzheimer’s disease
Zhang, J., Kong, G., Yang, J., Pang, L., & Li, X. (2025) · European journal of medical research · doi:10.1186/s40001-025-02886-9 · Cited by 301
“The progressive cascade of AD characterized by a prolonged 15–25 years preclinical phase of silent pathology, ultimately progresses through mild cognitive impairment to significant dementia [2, 13].”
García-Morales, V., González-Acedo, A., Melguizo-Rodríguez, L., Pardo-Moreno, T., Costela-Ruiz, V. J., Montiel-Troya, M., & Ramos-Rodríguez, J. J. (2021) · Biomedicines · doi:10.3390/biomedicines9121910 · Cited by 104
“Among the pharmacological alternatives available, acetylcholinesterase inhibitors (AChEIs) stand out [97].”
BackgroundInfluentialProgress and Challenges in Targeted Protein Degradation for Neurodegenerative Disease Therapy
Fang, Y., Wang, J., Zhao, M., Zheng, Q., Ren, C., Wang, Y., & Zhang, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00844 · Cited by 100
Arjunan, A., Sah, D. K., Woo, M., & Song, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-00966-z · Cited by 111
“Alzheimer’s disease (AD) AD is characterized by a progressive cognitive decline affecting around 25 million individuals worldwide [58], and causes difficulties in learning and memory, language, and executive motor function [59].”
BackgroundGut Microbiota, an Additional Hallmark of Human Aging and Neurodegeneration
Molinero, N., Antón‐Fernández, A., Hernández, F., Ávila, J., Bartolomé, B., & Moreno-Arribas, M. V. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.02.014 · Cited by 110
Hassan, A. S., Morsy, N. M., Aboulthana, W. M., & Ragab, A. (2023) · RSC Advances · doi:10.1039/d3ra00297g · Cited by 99
Alzheimer’s disease as type 3 diabetes: understanding the link and implications
Kciuk, M., Kruczkowska, W., Gałęziewska, J., Wanke, K., Kałuzińska-Kołat, Ż., Aleksandrowicz, M., & Kontek, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252211955 · Cited by 98
“However, no disease-modifying drug has been developed yet, though therapeutic interventions such as acetylcholinesterase inhibitors and NMDA receptor antagonists can temporarily enhance cognitive function and improve quality of life [292].”
Multiple neurological effects associated with exposure to organophosphorus pesticides in man
Jokanović, M., Olekšák, P., & Kuča, K. (2022) · Toxicology · doi:10.1016/j.tox.2022.153407 · Cited by 99
Karvandi, M. S., Hesari, F. S., Aref, A. R., & Mahdavi, M. (2023) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2023.1105247 · Cited by 114
“However, there are still so many studies to alleviate disease symptoms and extend life span (Breijyeh and Karaman, 2020).”
BackgroundOuyang, Q., Liu, K., Zhu, Q., Deng, H., Le, Y., Ouyang, W., Yan, X., Zhou, W., & Tong, J. (2022) · Small · doi:10.1002/smll.202107534 · Cited by 94
ABC transporters: human disease and pharmacotherapeutic potential
Moore, J. M., Bell, E. L., Hughes, R. O., & Garfield, A. S. (2022) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2022.11.001 · Cited by 101
Culberson, J. W., Kopel, J. J., Sehar, U., & Reddy, P. H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102001 · Cited by 111
Development of Phenothiazine Hybrids with Potential Medicinal Interest: A Review
Posso, M. C., Domingues, F., Ferreira, S. M. P., & Silvestre, S. (2022) · Molecules · doi:10.3390/molecules27010276 · Cited by 97
“Therefore, inhibitors of these enzymes can prevent acetylcholine destruction in synapses [54].”
BackgroundMediterranean diet and cognitive function: From methodology to mechanisms of action
Siervo, M., Shannon, O. M., Llewellyn, D. J., Stephan, B. C., & Fontana, L. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.018 · Cited by 86
Brain modulation by the gut microbiota: From disease to therapy
Mitra, S., Dash, R., Nishan, A. A., Habiba, S. U., & Moon, I. S. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2022.12.001 · Cited by 91
Moussa, N., & Dayoub, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101729 · Cited by 102
“AD is one of the most common causes of dementia and it is a significant public health concern (Breijyeh et al.,2020; McGirr et al., 2020; Scheltens et al., 2021).”
Amyloid-related Imaging Abnormalities in Alzheimer Disease Treated with Anti–Amyloid-β Therapy
Agarwal, A., Gupta, V., Brahmbhatt, P., Desai, A., Vibhute, P., Joseph-Mathurin, N., & Bathla, G. (2023) · RadioGraphics · doi:10.1148/rg.230009 · Cited by 90
Recent applications of EEG-based brain-computer-interface in the medical field
Liu, X., Wang, W.-L., Liu, M., Chen, M., Pereira, T., Doda, D. Y., Ke, Y., Wang, S., Dong, W., Tong, X., et al. (2025) · Military Medical Research · doi:10.1186/s40779-025-00598-z · Cited by 167
“The primary symptoms include a decline in cognitive function and changes in behavioral patterns, which can ultimately lead to death in severe cases [249].”
An overview of the genes and biomarkers in Alzheimer’s disease
Krishnamurthy, H. K., Jayaraman, V., Krishna, K., Wang, T., Bei, K., Changalath, C., & Rajasekaran, J. J. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102599 · Cited by 98
“Disruptive behaviors are common in ≈ 50% of AD patients (Breijyeh and Karaman, 2020).”
Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
Vogt, A.-C. S., Jennings, G. T., Mohsen, M. O., Vogel, M., & Bachmann, M. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043895 · Cited by 84
“AD is an irreversible neurodegenerative disorder, which is considered a leading world health concern [100].”
BackgroundInfluentialAlzheimer’s disease as a viral disease: Revisiting the infectious hypothesis
Bruno, F., Abondio, P., Bruno, R., Ceraudo, L., Paparazzo, E., Citrigno, L., Luiselli, D., Bruni, A. C., Passarino, G., Colao, R., et al. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102068 · Cited by 88
The role of glycogen synthase kinase 3 beta in neurodegenerative diseases
Yu, H., Xiong, M., & Zhang, Z. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1209703 · Cited by 268
“As the disease advances, walking difficulties, speech impairments, and swallowing problems become prevalent (Breijyeh and Karaman, 2020).”
BackgroundLiu, W., Deng, W., Gong, X., Ou, J., Yu, S., & Chen, S. (2025) · BMC Public Health · doi:10.1186/s12889-025-22378-z · Cited by 106
“As the disease progresses, dementia patients may have trouble recognizing relatives and friends, speaking, and in the later stages, swallowing and urinating [7].”
Interactions between glial cells and the blood-brain barrier and their role in Alzheimer's disease
Zhao, M., Jiang, X., Zhang, H., Sun, J., Pei, H., Ma, L., Cao, Y., & Li, H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101483 · Cited by 99
Ramos, H., Moreno, L., Pérez‐Tur, J., Cháfer‐Pericás, C., García‐Lluch, G., & Pardo, J. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020207 · Cited by 95
“According to the cholinergic hypothesis, Alzheimer’s disease is due to a decrease in acetylcholine synthesis [69].”
BackgroundLi, Z., Hwang, K., Li, K., Wu, J., & Ji, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-23656-1 · Cited by 101
A one-two punch targeting reactive oxygen species and fibril for rescuing Alzheimer’s disease
Wang, J., Shangguan, P., Chen, X., Zhong, Y., Lin, M., He, M., Liu, Y., Zhou, Y. L., Pang, X., Han, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44737-x · Cited by 91
“approved drugs were developed to treat AD although pouring tremendous investments, e.g., acetylcholinesterase inhibitors, N-methyl D-aspartate (NMDA) receptor antagonists, anti-in fl ammatory agents, and monoclonal antibody 11 – 13 .”
Speech based detection of Alzheimer's disease: a survey of AI techniques, datasets and challenges
Ding, K., Chetty, M., Noori Hoshyar, A., Bhattacharya, T., & Klein, B. (2024) · Artificial Intelligence Review · doi:10.1007/s10462-024-10961-6 · Cited by 82
“Pharmacological interventions for AD are limited to managing symptomatic manifestations, without providing curative or preventive effects for the underlying disease process (Breijyeh and Karaman 2020).”
An Attention-Based 3D CNN With Multi-Scale Integration Block for Alzheimer's Disease Classification
Wu, Y., Zhou, Y., Zeng, W., Qian, Q., & Song, M. (2022) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2022.3197331 · Cited by 111
“Since current clinical studies have not found effective means to reverse this disease, early diagnosis of AD is the only way to suppress the onset of the disease and improve the quality of life for patients [2]–[5].”
BackgroundMeng, K., Jia, H., Hou, X., Zhu, Z., Lu, Y., Feng, Y., Feng, J., Xia, Y., Tan, R., Cui, F., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13020327 · Cited by 91
“AD is a chronic progressive neurodegenerative disorder characterized by A β deposition in brain tissue forming senile plaques (SPs), neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau proteins, and synapse loss [33].”
New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 against Neurological Diseases
Sun, Y., Yang, Y., Liu, S., Yang, S., Chen, C., Lin, M., Zeng, Q., Long, J., Yao, J., Yi, F., et al. (2022) · Cells · doi:10.3390/cells11162529 · Cited by 86
“Other factors can cause neurodegeneration, such as neuroinflammation, oxidative stress, and cholinergic neuron damage [47].”
BackgroundSyntheses, reactivity, and biological applications of coumarins
Citarella, A., Vittorio, S., Dank, C., & Ielo, L. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1362992 · Cited by 92
“…fi ed, some key factors related to the neurodegeneration process have been identi fi ed, such as the loss of cholinergic neurons (cholinergic hypothesis), accumulation of A β amyloid fi brils (amyloid hypothesis) and τ -protein, oxidative stress and neuroin fl ammation (Breijyeh and Karaman, 2020).”
BackgroundAğagündüz, D., Bingöl, F. G., Çelik, E., Cemali, Ö., Özenir, Ç., Özoğul, F., & Capasso, R. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03609-y · Cited by 82
“Alzheimer’s disease risk factors can be listed as age and gender, head injuries, cardiovascular diseases, lifestyle, environmental factors, diet, infection, genetic factors, obesity and other diseases such as diabetes [92].”
BackgroundAlzheimer’s Disease Diagnosis Using Machine Learning: A Survey
Dara, O. A., López-Guede, J. M., Raheem, H. I., Rahebi, J., Zulueta, E., & Fernández‐Gámiz, U. (2023) · Applied Sciences · doi:10.3390/app13148298 · Cited by 99
“Another aspect of the problem is the character of the zoning, which necessitates the identification of Alzheimer’s-affected areas [12].”
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Taliyan, R., Kakoty, V., Sarathlal, K. C., Kharavtekar, S. S., Karennanavar, C. R., Choudhary, Y. K., Singhvi, G., Riadi, Y., Dubey, S. K., & Kesharwani, P. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.044 · Cited by 80
Haddad, H. W., W. Malone, G., J. Comardelle, N., E. Degueure, A., M. Kaye, A., & D. Kaye, A. (2022) · Health Psychology Research · doi:10.52965/001c.31925 · Cited by 71
Curcumin, inflammation, and neurological disorders: How are they linked?
Garodia, P., Hegde, M., Kunnumakkara, A. B., & Aggarwal, B. B. (2023) · Integrative Medicine Research · doi:10.1016/j.imr.2023.100968 · Cited by 78
Rezaee, D., Saadatpour, F., Akbari, N., Zoghi, A., Najafi, S., Beyranvand, P., Rarani, F. Z., Rashidi, M. A., Bagheri‐Mohammadi, S., & Bakhtiari, M. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102090 · Cited by 79
Singh, K., Bhushan, B., Chanchal, D. K., Sharma, S. K., Rani, K., Yadav, M. K., Porwal, P., Kumar, S., Sharma, A., Virmani, T., et al. (2023) · Behavioural Neurology · doi:10.1155/2023/8825358 · Cited by 97
“%) and a decline in emotional or behavioural dysregulation (such as irritability and restlessness) [59].”
BackgroundPagotto, G. L. D. O., Santos, L. M. O. D., Osman, N., Lamas, C. B., Laurindo, L. F., Pomini, K. T., Guissoni, L. M., Lima, E. P. D., Goulart, R. D. A., Catharin, V. M. C. S., et al. (2024) · Antioxidants · doi:10.3390/antiox13060651 · Cited by 67
Lim, A. C., Barnes, L. L., Weissberger, G. H., Lamar, M., Nguyen, A. L., Fenton, L. E., Herrera, J., & Han, S. D. (2023) · Communications Medicine · doi:10.1038/s43856-023-00333-6 · Cited by 90
Caspases in Alzheimer’s Disease: Mechanism of Activation, Role, and Potential Treatment
Wójcik, P., Jastrzębski, M. K., Zięba, A., Matosiuk, D., & Kaczor, A. A. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03847-1 · Cited by 89
“3), and PSEN2 (encoding presenilin 2 on chromosome 1q31-q42) and in more common but incompletely penetrant genetic variants such as APOE [31, 34].”
BackgroundLCADNet: a novel light CNN architecture for EEG-based Alzheimer disease detection
Kachare, P. H., Puri, D., Sangle, S. B., Al–Shourbaji, I., Jabbari, A., Kirner, R., Alameen, A. A. M., Migdady, H., & Abualigah, L. (2024) · Physical and Engineering Sciences in Medicine · doi:10.1007/s13246-024-01425-w · Cited by 91
Illakiya, T., Karthik, R., Siddharth, M. V., Mishra, R., & Udainiya, A. (2023) · Bioengineering · doi:10.3390/bioengineering10060714 · Cited by 74
“It is the most common form of dementia and leads to a progressive decrease in thinking, abnormal behavior and social skills that affect a person’s capacity to live independently [1].”
BackgroundValverde-Salazar, V., Ruiz-Gabarre, D., & García‐Escudero, V. (2023) · Antioxidants · doi:10.3390/antiox12071460 · Cited by 85
“These Aβmonomers can then aggregate to different extents, giving raise to the mentioned plaques that would then mediate the pathological effects described in the disease [43,44], although evidence from the past decade points toward oligomeric forms as the main drivers of the disease [5,45] (Figure 1 (A)).”
BackgroundInfluentialSTEADYNet: Spatiotemporal EEG analysis for dementia detection using convolutional neural network
Kachare, P. H., Sangle, S. B., Puri, D., Khubrani, M. M., & Al–Shourbaji, I. (2024) · Cognitive Neurodynamics · doi:10.1007/s11571-024-10153-6 · Cited by 85
“Dementia manifests as symptoms resulting from the impaired function of specific brain cell groups, impacting desires, reactions, and movement (Breijyeh and Karaman 2020).”
Pasquini, S., Contri, C., Merighi, S., Gessi, S., Borea, P. A., Varani, K., & Vincenzi, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031219 · Cited by 77
“Memantine, an NMDA receptor non-competitive antagonist, has been currently approved to treat the cognitive symptoms of AD [147].”
BackgroundClinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review
Liang, Y., Doré, V., Rowe, C. C., & Krishnadas, N. (2024) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-230181 · Cited by 80
“Currently approved treatments for AD include cholinesterase enzyme inhibitors and N-methyl D-aspartate receptor antagonists, which are symptomatic treatments [3].”
Luteolin for neurodegenerative diseases: a review
Jayawickreme, K., Ekwosi, C., Anand, A., Andres‐Mach, M., Właź, P., & Socała, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00610-8 · Cited by 80
“The pathology identified is Aβ peptide’s accumulation in the medial temporal lobe and neocortical structures of the brain resulting in neuritic plaques and neurofibrillary tangles [ 77].”
BackgroundInfluentialLi, Y., Liu, Y., Yu, X., Xu, Y., Pan, X., Sun, Y. E., Wang, Y., Song, Y.-H., & Shen, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02013-w · Cited by 95
Dietary Polyphenols as Therapeutic Intervention for Alzheimer’s Disease: A Mechanistic Insight
Bukhari, S. N. A. (2022) · Antioxidants · doi:10.3390/antiox11030554 · Cited by 76
“Alzheimer’s disease has a well-documented neuropathology, which is characterized by the formation of extracellular amyloid plaques and intracellular Tau neurofibrillary tangles (NFTs) in the medial temporal lobe and neocortical structures in the brain [2].”
BackgroundDysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases
Gentile, G., Morello, G., Cognata, V. L., Guarnaccia, M., Conforti, F. L., & Cavallaro, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12050770 · Cited by 72
“AD represents the most common ND of aging and the leading cause of dementia worldwide and is characterized by the accumulation of amyloid-β (Aβ) and tau aggregates in different brain areas [2,5].”
BackgroundCaffeic acid loaded into engineered lipid nanoparticles for Alzheimer's disease therapy
Andrade, S., Pereira, M. D. C., & Loureiro, J. A. (2023) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2023.113270 · Cited by 74
Advances in the study of IL-17 in neurological diseases and mental disorders
Lu, Y., Zhang, P., Xu, F., Zheng, Y., & Zhao, H. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1284304 · Cited by 82
“Aging, genetic factors, head injuries, vascular diseases, infections, and environmental factors are the main risk factors for the disease (84).”
BackgroundCryo-EM structures of lipidic fibrils of amyloid-β (1-40)
Frieg, B., Han, M., Giller, K., Dienemann, C., Riedel, D., Becker, S., Andreas, L. B., Griesinger, C., & Schroeder, G. F. (2024) · Nature Communications · doi:10.1038/s41467-023-43822-x · Cited by 74
“Cryo-EM structures of lipidic fibrils of amyloid-β (1-40)”
Metadata
- Authors
- Breijyeh, Z., & Karaman, R.
- Affiliations
- Al-Quds University (PS)
- Corresponding author
- Karaman, Rafik
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2020-12-08
- Volume
- 25
- Issue
- 24
- Pages
- 5789
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC7764106
- OpenAlex
- W3112948680
- Cited by
- 2,789
- References
- 149
- Citations by year
- 2026: 418 · 2025: 708 · 2024: 733 · 2023: 541 · 2022: 310 · 2021: 79
- FWCI
- 29.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, dementia, cholinergic hypothesis, amyloid hypothesis, risk factors, cholinesterase inhibitors, NMDA receptor antagonists, tau protein, amyloid-beta, neuroinflammation, oxidative stress, disease-modifying therapy, molecular chaperones, natural compounds, drug development
- MeSH terms
- Alzheimer Disease, Animals, Disease Susceptibility, Humans, Risk Factors, Severity of Illness Index, Biomarkers, Amyloid beta-Peptides, tau Proteins, Risk Assessment, Disease Management, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.